The short version of Research peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-06. Anything still debated is marked as such rather than presented as settled.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
== Political career == In 1983, he founded Unión para la Apertura Universitaria which won the students' union elections in the Faculty of Law in 1987, 1988 and 1989. He has been described as the "Godfather of the new style and method of university politics". In 1987, he was elected to the City of Buenos Aires Deliberative Council for Unión del Centro Democrático. He proposed reducing the number of members of the city legislature from 60 to 30. He was a large shareholder of the online broker Patagon when it was sold in 2000, before the dotcom bubble crash, for 750 million dollars. Ahead of the 2023 general election, Maslatón announced his intention to run for president as part of the La Libertad Avanza (LLA) coalition. He intended to dispute the coalition's nomination against Milei in the PASO primaries. On 20 January 2023, the coalition refused his request to contest the nomination. Maslatón then stood back from the contest and announced he would remain a member of LLA.
==== Beginning of the conflict ==== The report claimed that open hostilities started "... with a large-scale Georgian military operation against the town of Tskhinvali and the surrounding areas, launched in the night of 7 to 8 August 2008", but "... any explanation of the origins of the conflict cannot focus solely on the artillery attack on Tskhinvali in the night of 7/8 August", since "... it was only the culminating point of a long period of increasing tensions, provocations and incidents", and there was "... no way to assign overall responsibility for the conflict to one side alone." The beginning of the armed conflict between Georgia and South Ossetia was dated by the commission to 7 August 2008 at 23.35; however, the commission acknowledged that "a violent conflict had already been going on before in South Ossetia", and "President Saakashvili's order on 7 August 2008 at 23.35 and the ensuing military attack on Tskhinvali [...] has to be seen as but one element in an on-going chain of events for military violence had also been reported before the outbreak of the open hostilities on 7 August 2008." It is believed that direct military confrontation between Russia and Georgia began on 8 August 2008.
== Criticisms == In 2013, studies of autologous bone marrow stem cells on ventricular function were found to contain "hundreds" of discrepancies. Critics report that of 48 reports, just five underlying trials seemed to be used, and that in many cases whether they were randomized or merely observational accepter-versus-rejecter, was contradictory between reports of the same trial. One pair of reports of identical baseline characteristics and final results, was presented in two publications as, respectively, a 578-patient randomized trial and as a 391-subject observational study. Other reports required (impossible) negative standard deviations in subsets of people or contained fractional subjects, negative NYHA classes. Overall, many more people were reported as having receiving stem cells in trials, than the number of stem cells processed in the hospital's laboratory during that time. A university investigation, closed in 2012 without reporting, was reopened in July 2013. In 2014, a meta-analysis on stem cell therapy using bone-marrow stem cells for heart disease revealed discrepancies in published clinical trial reports, whereby studies with a higher number of discrepancies showed an increase in effect sizes. Another meta-analysis based on the intra-subject data of 12 randomized trials was unable to find any significant benefits of stem cell therapy on primary endpoints, such as major adverse events or increase in heart function measures, concluding there was no benefit.
== YouTube career == Pansino began her YouTube channel in 2010 after she was encouraged by a few of her friends who also worked on YouTube, and she started making videos to get more comfortable in front of a camera. After her early baking videos gained a steady following, viewers eventually started to request more content. Because she had never seen a baking show on television or the Internet, Pansino decided to create the Nerdy Nummies series. She decided to use the last name "Pansino" online, which was her maternal grandmother’s maiden name. She later revealed that in her early years of YouTube, while she was still working as an actress, she was given the ultimatum by her agent to choose between acting and YouTube. She remained adamant that she would not quit YouTube, despite the uncertainty involved. Pansino told Cosmopolitan in 2015: "At this point, I wasn't making any money on YouTube. I knew that it was possible to do that but I wasn't making a dime. I decided, I'm going to do this. I'm not going to let YouTube go." As of April 2026, Pansino's channel has attained over 5.1 billion views and 14.8 million subscribers, making it the most popular cooking channel on YouTube. She has received several accolades. In 2013, she won the Shorty Award for Best Foodie, Chef, or Food Lover in Social Media. She has also received five Streamy Award nominations for her work on Nerdy Nummies. In 2018, Pansino officially reached 10 million subscribers on YouTube, earning her the Diamond Play Button given by the company.
22 September It is reported that eight-year-old Aditi Shankar has become the first child in the UK to receive a kidney transplant that will not require her to take medication to prevent the organ being rejected, and that she is healthy and has returned to school. In his first statement since further allegations were made against him, Russell Brand posts a video on social media describing his week as "extraordinary and distressing". 23 September The government's home energy efficiency taskforce is scrapped. Members of the anti-monarchist pressure group Republic stage what they describe as the "first-ever" protest inside Buckingham Palace. 24 September – Home Secretary Suella Braverman orders a review into armed policing, after 300 firearms officers hand in their weapons, following concerns over a police officer charged with murdering 24-year-old Chris Kaba. Most of the officers return to their duties the following day. 25 September A hearing at Manchester Crown Court determines that Lucy Letby will face a retrial for one of the six counts of attempted murder that the jury at her original trial was unable to reach a verdict on; a provisional trial date is set for 10 June 2024. The Metropolitan Police are to investigate allegations of non-recent sexual offences following recent reports about comedian Russell Brand. 26 September Home Secretary Suella Braverman tells a US think tank the 1951 Refugees Convention is no longer fit for the modern age, and that being discriminated against for being gay or female should not be enough to qualify for refugee status.
Sources: en.wikipedia.org
=== Post-translational modifications === Whilst detailed comparison of the MS data with predictions based on the known protein sequence may be used to define post-translational modifications, targeted approaches to data acquisition may also be used. For instance, specific enrichment of phosphopeptides may assist in identifying phosphorylation sites in a protein. Alternative methods of peptide fragmentation in the mass spectrometer, such as ETD or ECD, may give complementary sequence information.
=== Tolerance dose === In 1931, the U.S. Advisory Committee on X-Ray and Radium Protection (ACXRP, now the National Council on Radiation Protection and Measurements, NCRP), founded in 1929, published the results of a study on the so-called tolerance dose, on which a scientifically based radiation protection guideline was based. Exposure limits were gradually lowered. In 1936 the tolerance dose was 0.1 R/day. The unit "R" (the X-ray) from the CGS unit system has been obsolete since the end of 1985. Since then, the SI unit of ion dose has been "coulomb per kilogram".
Already chief scientist, Van de Graaff joined HVEC full-time in 1960. He worked with colleagues to introduce the industrial core transformer. Focused on scientific hypothesis at the frontier of the field, he championed development of the company's most ambitious accelerator. Theoretical models predicted an "island of stability" of superheavy elements—heavy atoms that would resist rapid radioactive decay despite lying beyond uranium on the periodic table. Van de Graaff believed that stable superheavy elements could provide nuclear fuel for long-distance space missions or enable compact nuclear weapons, making superheavy ion synthesis the top priority for accelerator research. The proposed 20-megavolt Transuranium Accelerator (XTU) pushed HVEC accelerators towards this frontier. HVEC invested more than $4.6 million in two XTU prototypes (equivalent to $44.4 million in 2025). Anticipating that laboratories would compete to acquire machines capable of historic discoveries, leadership adopted a "build first and seek customers later" approach. During the XTU's construction in 1967–68, federal support for basic nuclear physics declined sharply. The Vietnam War and Great Society programs drew resources away from fundamental research. Simultaneously, the discovery of sub-atomic quarks put the high-energy frontier of physics research beyond the reach of Van de Graaff accelerators. By the time the XTU passed preliminary tests the following year, the U.S. Atomic Energy Commission had said it would not fund purchases.
=== Morning sickness === Doxylamine is used in the combination drug pyridoxine/doxylamine to treat morning sickness (nausea and vomiting of pregnancy). It is the only medication approved by the United States Food and Drug Administration for the treatment of morning sickness.
Sources: en.wikipedia.org
Silica gel may be doped with a moisture indicator that gradually changes its color when it transitions from the anhydrous (dry) state to the hydrated (wet) state. Common indicators are cobalt(II) chloride and methyl violet. Cobalt (II) chloride is deep blue when dry and pink when wet, but it is toxic and carcinogenic, and was reclassified by the European Union in July 2000 as a toxic material. Methyl violet may be formulated to change from orange to green, or orange to colorless. It also is toxic and potentially carcinogenic, but is safe enough to have medicinal uses. Ferric and ferrous salts, sometimes combined with small amounts of sodium hydroxide, provide a better alternative. In particular, ferric sulfate and double salts like ammonium iron(III) sulfate (iron alum), ammonium iron(II) sulfate, and potassium iron(III) sulfate all result in a color change from amber/yellow when dry to colorless/white when saturated.
== Prognosis == As there is no known cure, the average life expectancy of people with progeria is 13 years, as of 2003. At least 90 percent of patients die from complications of atherosclerosis, such as heart attack or stroke. Mental development is not adversely affected; in fact, intelligence tends to be average to above average. With respect to the features of aging that progeria appears to manifest, the development of symptoms is comparable to aging at a rate eight to ten times faster than normal. With respect to those that progeria does not exhibit, patients show no neurodegeneration or cancer predisposition. They also do not develop conditions that are commonly associated with accumulation of damage, such as cataracts (caused by UV exposure) and osteoarthritis. Although there may not be any successful treatments for progeria itself, there are treatments for the problems it causes, such as arthritic, respiratory, and cardiovascular problems, and recent medicinal breakthroughs enabled one patient to live until age 28. People with progeria have normal reproductive development, and there are known cases of women with progeria who delivered healthy offspring.
== History == 3,4-DMA was first described in the scientific literature by Gordon Alles by 1932. Its effects in humans were first described by Mahlon David Fairchild by 1963. Subsequently, the drug was described in greater detail by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.